Shanghai IxCell Biopharmaceutical Co., Ltd.
PrivateLast Round
Early Funding
Aug 26, 2025
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Shanghai IxCell Biopharmaceutical Co., Ltd. is a biotechnology company that specializes in the development and industrial production of cell-based drugs, including mesenchymal stem cell, induced pluripotent stem cell, and immune cell therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shanghai IxCell Biopharmaceutical Co., Ltd. Comparables
Compare Shanghai IxCell Biopharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| uBriGene Biosciences | 83% | |
| Jiangsu Hillgene Biopharmaceutical Co., Ltd. | 83% | |
| OBiO Technology | 81% | |
Shanghai IxCell Biopharmaceutical Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Aug 26, 2025 | ||||
| Series B | Mar 12, 2025 | ||||
| Series B Extension | Dec 16, 2022 | ||||
| Series B | Sep 29, 2022 | ||||
| Early Funding | Mar 1, 2021 | ||||
Series A | Nov 13, 2020 |
Shanghai IxCell Biopharmaceutical Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kailian Capital | Early Funding, Series B |
| Shenzhen Dachen Caizhi Venture Capital Management | Series B |
| Guangdong Technology Financial Group | Series B Extension |
| Tasly Capital | Series A |
| SDIC Venture Capital | Series B Extension |
| Zhejiang Huaou Venture Capital | Early Funding, Series A |
| 新丝路金控 | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 26, 2025
Raised capital from Kailian Capital and Zhejiang Huaou Venture Capital.
- Mar 12, 2025
Completed a Series B funding round.
Shanghai IxCell Biopharmaceutical Co., Ltd. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Shanghai IxCell Biopharmaceutical Co., Ltd.'s valuation, stock price, and market status.